Literature DB >> 22226105

Understanding chronic GVHD from different angles.

Bruce Blazar1, Eric S White, Daniel Couriel.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22226105      PMCID： PMC3551472          DOI： 10.1016/j.bbmt.2011.10.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  29 in total

1.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

2.  Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.

Authors:  José A Pérez-Simón; Cristina Encinas; Fernando Silva; Maria José Arcos; María Díez-Campelo; Fermín M Sánchez-Guijo; Enrique Colado; Jesús Martín; Lourdes Vazquez; Consuelo Del Cañizo; Dolores Caballero; Jesús San Miguel
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.

Authors:  Joseph Pidala; Jongphil Kim; Claudio Anasetti; Taiga Nishihori; Brian Betts; Teresa Field; Janelle Perkins
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

5.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.

Authors:  Stephanie k Lee; E Francis Cook; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

6.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.

Authors:  Marijke R Canninga-van Dijk; Hanneke M van der Straaten; Rob Fijnheer; Cornelus J Sanders; Jan G van den Tweel; Leo F Verdonck
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

7.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.

Authors:  Voravit Ratanatharathorn; Lois Ayash; Christopher Reynolds; Samuel Silver; Pavan Reddy; Michael Becker; James L M Ferrara; Joseph P Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2003-08       Impact factor: 5.742

8.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

9.  New classification of chronic GVHD: added clarity from the consensus diagnoses.

Authors:  M Arora; S Nagaraj; J Witte; T E DeFor; M MacMillan; L J Burns; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2008-09-15       Impact factor: 5.483

10.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease.

Authors:  B-S Cho; C-K Min; K-S Eom; Y-J Kim; H-J Kim; S Lee; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-C Kim
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528
View more
  4 in total

Review 1.  Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.

Authors:  Hideki Nakasone; Bita Sahaf; David B Miklos
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

Review 2.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

3.  Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease.

Authors:  Ethan Strattan; Senthilnathan Palaniyandi; Reena Kumari; Jing Du; Natalya Hakim; Timothy Huang; Melissa V Kesler; C Darrell Jennings; Jamie L Sturgill; Gerhard C Hildebrandt
Journal:  Front Immunol       Date:  2019-10-18       Impact factor: 7.561

4.  Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD.

Authors:  Y Inamoto; M Jagasia; W A Wood; J Pidala; J Palmer; N Khera; D Weisdorf; P A Carpenter; M E D Flowers; D Jacobsohn; P J Martin; S J Lee; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2014-01-27       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.